Nectar Lifesciences

Nectar Lifesciences Limited

Type	Public
Traded as	BSE: 532649 NSE: NECLIFE
Industry	Pharmaceuticals
Founded	1995
Headquarters	Chandigarh, India
Key people	Sanjiv Goyal, Chairman and Managing Director, Dinesh Dua, CEO and Director, Aryan Goyal,Executive Director
Products	Cephalosporins,
Revenue	11.2 billion
Net income	1.02 billion
Employees	2200
Website	www.neclife.com

Nectar Lifesciences Finished Dosage Facility

Nectar Lifesciences Limited (BSE: 532649, NSE: NECLIFE) is an integrated pharmaceutical company in India that manufactures high quality generic products for EU and USA. The company is the largest manufacturer of Cefuroxime Axetil API and Cefixime API in the world and manufactures 25% of menthol (raw) of the world.

History

The company is promoted by Goyal family and was incorporated in June 1995. The company went public in July 2005 with simultaneous listings on Bombay Stock Exchange and the National Stock Exchange of India. In 2010 New Silk Route PE invested INR 2.5 billion in the company.

Management

The company's chairman and Managing Director is Mr Sanjiv Goyal.

Executive Director: Mr Aryan Goyal

CEO: Mr Dinesh Dua

Market Cap

The current market capitalization is about INR 9 billion (US$ 300 million).

Products

Nectar Lifesciences manufactures oral and sterile active pharmaceutical ingredients, finished dosages and phytochemicals. The company is also in business of providing leading pharmaceutical organizations with contract research and manufacturing services. It also Manufactures Empty Hard Gelatin Capsules.

Cephalosporins

• Cefazolin Sodium
• Cefdinir
• Cefepime HCl
• Cefixime
• Cefoperazone Sodium
• Cefotaxime Sodium
• Cefoxitin Sodium
• Cefpirome Sulphate
• Cefpodoxime Proxetil
• Cefprozil
• Ceftazidime Pentahydrate
• Ceftriaxone Sodium
• Cefuroxime Axetil
• Cefuroxime Sodium
• Cephalothin Sodium
• Cefditoren Pivoxil

External links

• Nectar Lifesciences: Official site